ENLV
Enlivex Therapeutics Ltd.- Healthcare
- Biotechnology
- $44M market cap
Forecast run · Oct 29, 2026Upside rank 1 of 3,186
Model Signal
ForecastQ Daily Probabilities
100.0%
19.5%
96.2%
Analyst Consensus
Recommendation2.25/5 Buy
Last price$2.61
Price target$15.00
Implied move+474.7%
Analysts4
ForecastQ Portfolios
ENLV is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.